Light Chain Bioscience has entered into two research collaborations and worldwide licensing agreements with Discoveric bio group.
The first collaboration aims at developing multi-specific antibodies directed against bacterial antigens for the treatment of multidrug-resistance. The objective of the second collaborative program is to develop brain penetrating multi-specific antibodies for the treatment of neurodegenerative disorders, including Alzheimer’s disease. In both programs Light Chain Bioscience will apply its proprietary platform technologies, enabling the generation of antibodies engaging multiple targets while maintaining a native human immunoglobulin structure. These collaborations bring discoveric bio’s expertise in these disease areas together with Light Chain Bioscience’s know-how in multi-specific antibody discovery and development. Under the terms of the agreement, Light Chain Bioscience will receive upfront and milestones payments, as well as tiered royalties on net sales of all products resulting from the collaboration. “We are thrilled to work closely with discoveric bio and bring forward novel modalities to treat diseases of growing need such as neurodegeneration as well as addressing the threat of multi-resistant pathogens” said Nicolas Fischer, Light Chain Bioscience’s Chief Executive Officer. “Even if fundamentally different, both bacterial infections and neurodegeneration are characterized by complex underlying mechanisms that can potentially be better tackled by engaging multiple targets simultaneously.”
About Light Chain Bioscience
Light Chain Bioscience is a clinical-stage company focused on the discovery and development of therapies based on bispecific and multi-specific antibody formats. Its proprietary κλ body platform allows for the identification of bispecific antibodies that fully retain the native sequence and structure on human antibodies. This unique property is of interest for long term treatment of patients. In immuno-oncology, Light Chain Bioscience focuses on the selective targeting of the checkpoint CD47 as well as T cell redirecting strategies. For more information, please visit www.lightchainbio.com
GENEVA, Switzerland, November 30th, 2020
